Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-AXL, Ab-2 Vector   (CAT#: GTVCR-WQ141MR)

This product GTVCR-WQ141MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting AXL. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Humanized
RefSeq NM_001278599.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-AXL, Ab-2 Vector (GTVCR-WQ141MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ107MR IVTScrip™ pT7-VEE-mRNA-Anti-RTN4, 6A3-IgG4 Vector Vector 6A3-IgG4
GTVCR-WQ2420MR IVTScrip™ pT7-VEE-mRNA-Anti-MAPT, RO-7105705 Vector Vector RO-7105705
GTVCR-WQ726MR IVTScrip™ pSP6-VEE-mRNA-Anti-SNCA, BIIB-054 Vector Vector BIIB-054
GTVCR-WQ007MR IVTScrip™ pT7-VEE-mRNA-IL1A Vector Vector IL1A
GTVCR-WQ2350MR IVTScrip™ pSP6-VEE-mRNA-Anti-LAG3, aLAG367 Vector Vector aLAG367
GTVCR-WQ1070MR IVTScrip™ pSP6-VEE-mRNA-Anti-MSTN, CSL-362-AML Vector Vector CSL-362-AML
GTVCR-WQ2064MR IVTScrip™ pT7-VEE-mRNA-Anti-TIGIT, MTIG-7192-A Vector Vector MTIG-7192-A
GTVCR-WQ175MR IVTScrip™ pT7-VEE-mRNA-Anti-SLAMF7, ABBV-383 Vector Vector ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW